Back to top

The PCT advantage

Sepsis is caused by an over-reactive immune response to blood-borne infection and leads to widespread inflammation.  Without timely and effective treatment, sepsis can cause tissue damage, organ failure, and death.

Procalcitonin (PCT) is a biomarker that offers advantages over other testing methods:

  • Higher specificity for bacterial infections 1-4
  • Rises within 3-6 hours after infectious challenge 5
  • Rapidly and reliably declines as septic infection resolves 4,5,6,7

PCT supports repsonsible antibiotic use

  • The ability of PCT to differentiate bacterial from viral infection allows for more appropriate administration of antibiotics
  • Monitoring PCT improves patient management and treatment

Enhance Lower Respiratory Tract Infection (LRTI) management

  • Distinguishing between bacterial and viral infections is challenging- especially in LRTI. 
  • Limitations exist with current testing procedures


Download the Lumipulse® G B•R•A•H•M•S PCT brochure now to receive more information.

Interested in learning more?

Join our evaluation program!


  1. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care  unit. Crit Care Med. 2000;28(4):977-983.
  2. Clec’h C, Ferriere F, Karoubi P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004;32(5):1166-1169.
  3. Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263-273.
  4. Harbarth S, Holeckova K, Pittet D, Ricou B, Grau GE, Vadas L. and Interleukin-8 in Critically Ill Patients Admitted. Am J Respir Crit Care Med. 2001;164:396-402.
  5. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24(8):888-889.
  6. Ball J, Venn R. The 21st International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 20-23 March 2001. Crit Care. 2001;5(3):138-141.
  7. Soni NJ, Samson DJ, Galaydick JL, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med. 2013;8(9):530-540.


Reagent developed in collaboration with B•R•A•H•M•S GmbH.
B•R•A•H•M•S PCT is a registered trademark of B•R•A•H•M•S GmbH.

FDI-483  03/18